GTBL has developed strong capabilities in Rifamycin intermediate chemistry and fermentation-driven manufacturing, enabling the production of key APIs used in anti-tuberculosis and antibiotic therapies.
Rifamycin Leadership - First to launch Rifampicin in India.
Our established expertise in manufacturing Rifamycin-derived APIs is supported by integrated fermentation, purification, and downstream processing capabilities.
A focused platform delivering consistent quality, reliable supply, and robust process control for critical antibiotic therapies.
Rifamycin Intermediate
Rifamycin S
Specialized formulationA high-purity rifamycin intermediate supporting downstream antibiotic synthesis and manufacturing processes.
Rifamycin O
Advanced derivativeA premium-quality rifamycin intermediate for pharmaceutical API manufacturing and research applications.
Anti-Tuberculosis API
Rifampicin
Anti-tuberculosis treatmentA cornerstone API in global TB therapy, manufactured through integrated fermentation and purification systems.
Rifapentine
Extended treatment optionA long-acting rifamycin derivative supporting latent TB infection management and preventive therapy protocols.
Gastrointestinal API
Rifaximin
Gastrointestinal applicationsA non-absorbable antibiotic designed for targeted gastrointestinal therapy with minimal systemic exposure.